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Cancer has become the leading cause of death 
among Americans today. In 2006, over 500,000 Ameri-
cans will die due to cancer [11]. Cancer is a highly 
complex disease to understand because it entails mul-
tiple cellular physiological systems such as cell signal-
ing and apoptosis [10]. Thus, the most common cancer 
treatments are limited to chemotherapy, radiation, 
and surgery. Limitations in cancer treatment are a 
result of current challenges seen in cancer therapies 
today, including lack of early disease detection, non-
specific systemic distribution, inadequate drug con-
centrations reaching the tumor, and inability to moni-
tor therapeutic responses. Poor drug delivery and 
residence at the target site leads to significant compli-
cations, such as multi-drug resistance.  
Nanotechnology has the potential to offer solu-
tions to these current obstacles in cancer therapies, 
because of its unique size (1-100nm) and large surface-
to-volume ratios [13]. Nanotechnologies may have 
properties of self-assembly, stability, specificity, drug 
encapsulation and biocompatibility as a result of their 
material composition [9]. The NCI Alliance for 
Nanotechnology in Cancer has identified the potential 
of nanotechnology, and aims to accelerate the applica-
tion of nanotechnologies in cancer research and clini-
cal development. This program is a comprehensive, 
systemized initiative encompassing both public and 
private sectors [8]. The program comprises of eight 
Centers of Cancer Nanotechnology Excellence (CCNE), 
twelve platform projects, and four interdisciplinary 
training programs across the nation 
[http://nano.cancer.gov]. Thus far, research programs 
within the Alliance have made remarkable advance-
ments in nanotechnology-cancer research. The objec-
tive of this article is to provide a brief review of these 
advances. 
In the April 2006 PNAS publication “Nanoparti-
cle-aptamer bioconjugates for cancer targeting”, 
Langer and Farhrokzad from the MIT-Harvard CCNE 
tested the effect of aptamer-targeted nanoparticles for 
treatment of prostate cancer. This novel approach of 
u s i n g  a p t a m e r s  a s  t a r g e t e d  l i g a n d s ,  o n  d r u g -
encapsulated nanoparticles, proved to be highly effec-
tive in targeting cancer cells and decreasing tumor size 
[6]. Aptamers are DNA or RNA oligonucleotides that 
fold in tertiary conformations, which then are able to 
bind to targeting antigens [4]. They are advantageous 
because aptamers are fairly small in size and, there-
fore, do not significantly impact the particle’s overall 
size. Also, aptamers are non-immunogenic and fairly 
stable with long circulation times in the body. Aptam-
ers have high affinity and specificity, which is an im-
portant requirement in targeting [5,6]. The use of these 
docetaxel-encapsulated nanoparticle-aptamer biocon-
jugates demonstrated a decrease in tumor size from 
approximately 300 mm3 to 120 mm3, as seen in Figure 
1. In addition to reducing tumor size, these targeting 
methods had fewer side effects on healthy cells within 
the body in comparison to current methods of chemo-
therapy [6]. 
A number of the projects within the Alliance are 
investigating methods to overcome the challenges in 
maintaining drug circulation and avoiding multi-drug 
resistance. Due to chemical compositions and lack of 
targeting, many current therapeutic agents are re-
moved from the body’s circulation by the reticuloen-
dothelial system (RES) or immune system [3]. In their 
June 2006 publication, Amiji and Langer addressed 
these challenges by developing poly(ethylene oxide)-
modified poly(beta-amino ester) (PEO-PbAE) 
nanoparticles. They studied the efficacy and toxicity 
levels of paclitaxel when it was administrated through 
PEO-PbAE nanoparticles in mice, bearing human 
ovarian adenocarcinoma xenograft. The PEO-PbAE 
polymer nanoparticles were significantly more effi-
cient in drug delivery, reducing toxicity and decreas-
ing tumor growth rates in comparison to the paclitaxel 
aqueous solution [3].  
The interaction between the PbAE polymeric core 
with the PEO modified surface gives particles hydro-
philic PEO components that decreases opsonization 
signal binding, and thus particles are less prone to 
phagocytes and macrophages [1-3,14,16]. Particles 
were pH-sensitive, allowing drug release only at cer-
tain pH conditions, similar to pH levels unique in 
tumor cells. As a result the PEO-PbAE nanoparticles Int. J. Biol. Sci. 2007, 3  109
demonstrated the greatest drug efficacy. After four 
weeks the PEO-PbAE nanoparticle had reduced tumor 
volume to 22% of the original volume, where as the 
aqueous solution only had reduced tumor volume to 
44% [3]. As these nanoparticles improve drug circula-
tion, they also decrease chances of multi-drug resis-
tance in long-term therapies. 
In further research, Kommareddy and Amiji re-
cently published their work on using poly(ethylene 
glycol) (PEG) surface modified thiolated gelatin 
nanoparticles to test drug and gene efficacy on breast 
cancer cells. Studies demonstrated prolonged circula-
tion due to the hydrophilic PEG-modified surfaces. 
The PEG-modified thiolated gelatin nanoparticles had 
a high half-life of 37.8 h in the tumor mass. Also, drug 
release was administrated through thiolated gelatin 
nanoparticles that are highly sensitive to reducing 
environments, similar to those found in tumor cells 
[12]. Through nanotechnology, nanoparticles can be 
modified in a numerous ways to prolong circulation, 
enhance drug localization, increase drug efficacy, and 
potentially decrease chances of multi-drug resistance. 
Nanotechnology is also overcoming challenges of 
early detection and imaging in current cancer thera-
pies. In July 2006, an article by Sathe et al. demon-
strated the use of nanotechnology in cancer detection 
[15]. Current detection methods are restricted in spec-
trum range, penetration depth, cell targeting, and 
signal/noise clarity [9]. The Nie team at the 
Emory/Georgia Tech CCNE has been focusing on the 
development of quantum dots to improve detection 
methods. In the study mentioned above, they devel-
oped dual-functioning beads comprised of quantum 
dots and iron oxide nanocrystals embedded in silica 
beads. These particles were able to target specific cells, 
due to the iron oxide crystals, and have high imaging 
qualities, due to the quantum dot component. Cur-
rently, they are determining ideal combinations of 
iron oxides and quantum dots that would give the 
best imaging qualities [15]. Through nanotechnology, 
highly sensitive and specific imaging agents are being 
developed with biocompatible and multi-functional 
properties. 
The role of the NCI Alliance is to monitor re-
search programs to ensure they are product-oriented 
and milestone driven [8,9]. Within the five-year fund-
ing period, the Alliance aims to increase advancement 
rates by conducting annual progress reports, monitor-
ing development and encouraging collaboration 
across the Alliance. This program is unique because it 
forms a strong network among the top researchers in 
the nation and encourages research advancement, so 
projects may reach clinical trial stages in the near fu-
ture [8]. As a result of the organization and framework 
of the Alliance, there are high prospects in developing 
highly efficient cancer therapies through the applica-
tion of nanotechnology.  
Figure 1. A. Prostate Cancer cells were induced in mice using LNCaP prostate epithelial cells. Tumor development was 
allowed for 21 days in all conditions. Tumor masses were studied over a 109 day period. Saline was used as the control in 
this case. Results demonstrated that the docetaxel-nanoparticle-aptamers reduced tumor volume to 120 mm
3 from 300 mm
3. 
The none-targeted docetaxel nanoparticles also reduced tumor mass, however not as significantly as the aptamer-targeted 
nanoparticles. B. Difference in tumor mass is visibly seen with images of the mice and corresponding tumors at the end 
point. Black arrows point to the position of the implanted tumor. (Source: Farokhzad et al. [6]. Figure copyrighted National 
Academy of Sciences, U.S.A. Permission obtained.) 
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